SciSparc Announced That It Has Signed A Non-binding Letter Of Intent With An Undisclosed Biotechnology Company To Pursue The Out-licensing Of Its SCI-160 Program For The Treatment Of Pain
Portfolio Pulse from Benzinga Newsdesk
SciSparc has signed a non-binding letter of intent with an undisclosed biotechnology company to out-license its SCI-160 program for pain treatment.
July 17, 2024 | 11:09 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
SciSparc has signed a non-binding letter of intent with an undisclosed biotechnology company to out-license its SCI-160 program for pain treatment. This could potentially lead to new revenue streams and partnerships for SciSparc.
The non-binding letter of intent indicates a potential future partnership and revenue stream for SciSparc, which is positive news for the company. However, the non-binding nature of the agreement means that it is not yet a certainty.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100